GlobeNewswire: BG Medicine, Inc. Contains the last 10 of 121 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T13:03:18ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/12/23/797949/0/en/BG-Medicine-Withdraws-510-k-Premarket-Notification-for-Proposed-Additional-Indication-for-the-BGM-Galectin-3-Test.html?f=22&fvtc=4&fvtv=13219BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test2015-12-23T12:50:00Z<![CDATA[WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in order to obtain regulatory clearance to market its BGM Galectin-3® Test for a potential new indication for use as an aid  in the assessment of the near-term risk of fatal cardiovascular events in older adults who have no prior history of cardiovascular disease, cerebrovascular disease or vascular disease.]]>https://www.globenewswire.com/news-release/2015/11/30/791366/0/en/License-and-Distribution-Agreement-Amended.html?f=22&fvtc=4&fvtv=13219License and Distribution Agreement Amended2015-11-30T12:40:00Z<![CDATA[Adoption of Automated Testing for Galectin-3 by Reference Laboratories Expected to Expand Adoption of Automated Testing for Galectin-3 by Reference Laboratories Expected to Expand]]>https://www.globenewswire.com/news-release/2015/11/17/787907/0/en/BG-Medicine-Reports-Third-Quarter-2015-Financial-Results.html?f=22&fvtc=4&fvtv=13219BG Medicine Reports Third Quarter 2015 Financial Results2015-11-17T12:50:20Z<![CDATA[WALTHAM, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three and nine months ended September 30, 2015.]]>https://www.globenewswire.com/news-release/2015/11/11/786332/0/en/BG-Medicine-Announces-Business-Update-Conference-Call-Information.html?f=22&fvtc=4&fvtv=13219BG Medicine Announces Business Update Conference Call Information2015-11-11T21:30:00Z<![CDATA[WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17, 2015, beginning at 8:30 a.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2015/09/15/768462/10149443/en/BG-Medicine-to-Begin-Trading-on-the-OTCQB.html?f=22&fvtc=4&fvtv=13219BG Medicine to Begin Trading on the OTCQB2015-09-15T17:27:26Z<![CDATA[WALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) -- ]]>https://www.globenewswire.com/news-release/2015/08/14/760902/10146146/en/BG-Medicine-Provides-Business-Update-and-Reports-Second-Quarter-2015-Financial-Results.html?f=22&fvtc=4&fvtv=13219BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results2015-08-14T20:43:16Z<![CDATA[Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S.]]>https://www.globenewswire.com/news-release/2015/08/13/760461/10145945/en/BG-Medicine-Prices-Underwritten-Public-Offering.html?f=22&fvtc=4&fvtv=13219BG Medicine Prices Underwritten Public Offering2015-08-13T12:35:06Z<![CDATA[WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3]]>https://www.globenewswire.com/news-release/2015/08/12/760257/10145881/en/BG-Medicine-Announces-Proposed-Underwritten-Public-Offering.html?f=22&fvtc=4&fvtv=13219BG Medicine Announces Proposed Underwritten Public Offering2015-08-12T20:28:48Z<![CDATA[WALTHAM, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- (NASDAQ:BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3]]>https://www.globenewswire.com/news-release/2015/07/27/755180/10143155/en/BG-Medicine-Welcomes-U-S-Market-Introduction-of-Automated-Galectin-3-Test-at-the-2015-American-Association-for-Clinical-Chemistry-Annual-Meeting.html?f=22&fvtc=4&fvtv=13219BG Medicine Welcomes U.S. Market Introduction of Automated Galectin-3 Test at the 2015 American Association for Clinical Chemistry Annual Meeting2015-07-27T12:00:00Z<![CDATA[WALTHAM, Mass., July 27, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that, in conjunction with the U.S. market introduction of automated testing for galectin-3, clinical and analytical performance data for galectin-3 testing using an Abbott ARCHITECT]]>https://www.globenewswire.com/news-release/2015/07/15/752243/10141786/en/BG-Medicine-Announces-Payoff-of-Secured-Term-Loan.html?f=22&fvtc=4&fvtv=13219BG Medicine Announces Payoff of Secured Term Loan2015-07-15T11:00:00Z<![CDATA[WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3]]>